Transient but Transformative: Sanofi’s mRNA CAR-T Enters in Vivo Race

Why It Matters

If validated clinically, Sanofi’s off‑the‑shelf, non‑viral CAR‑T could slash production costs and broaden patient access, reshaping the competitive landscape against bispecific antibodies and traditional autologous therapies.

Key Takeaways

• Sanofi uses LNP‑delivered mRNA for in‑vivo CAR‑T.
• Anti‑CD8 VHH nanobody improves T‑cell targeting efficiency.
• Preclinical mouse model shows tumor suppression, <5% liver uptake.
• Transient CAR expression enables repeat dosing, avoids insertional mutagenesis.
• CAR‑T market projected $23.6 bn by 2031, 25% CAGR.

Pulse Analysis

The CAR‑T field has been dominated by autologous, ex‑vivo processes that require patient‑specific cell harvesting, viral transduction, and weeks of manufacturing. Sanofi’s strategy, built on its 2021 acquisition of Translate Bio, leverages a large library of lipid nanoparticles to protect and ferry mRNA through the bloodstream. Coupled with the VHH nanobody technology from Tidal Therapeutics, the LNPs home to CD8‑positive cytotoxic T cells, delivering a transient CAR construct directly inside the patient’s immune system. This non‑viral, off‑the‑shelf model sidesteps the logistical bottlenecks that have limited CAR‑T scalability.

In murine studies, the optimized LN15 formulation demonstrated superior T‑cell transfection compared with alternative ligands and encoded a CD22‑specific CAR for B‑cell malignancies. The treatment produced measurable tumor regression while keeping hepatic exposure under 5%, a notable safety improvement over conventional LNP delivery. Because the CAR is expressed from mRNA, its presence fades after a few days, reducing the risk of insertional mutagenesis and allowing clinicians to administer repeat doses if needed. However, the transient nature raises questions about durability of response and the potential for anti‑drug immunity, issues that upcoming human trials must address.

From a market perspective, the ability to manufacture CAR‑T products at scale without patient‑specific viral vectors could dramatically lower therapy costs and accelerate time‑to‑treatment. If efficacy matches that of existing autologous products, Sanofi’s platform may compete directly with bispecific antibodies and become a viable option in earlier lines of therapy. With the CAR‑T market projected to expand from $5 bn in 2024 to $23.6 bn by 2031, a successful in‑vivo mRNA approach could capture a sizable share of this growth, prompting broader industry investment in non‑viral, off‑the‑shelf immunotherapies.